Evaluation of Treatment Responses of COVID-19 Patients Receiving Hydroxychloroquine Treatment: a Retrospective Analysis in a Tertiary ReferenceHospital in Turkey

Basit Öğe Kaydı
dc.contributor.authorUNAT, Ömer Selim
dc.contributor.authorBATUM, Özgür
dc.contributor.authorANAR, Ceyda
dc.contributor.authorKİRAKLİ, Cenk
dc.contributor.authorKARADENİZ, Gülistan
dc.contributor.authorPOLAT, Gülru
dc.contributor.authorBÜYÜKŞİRİN, Melih
dc.date.accessioned2024-03-09T20:43:15Z
dc.date.available2024-03-09T20:43:15Z
dc.date.issued2022
dc.departmentİzmir Bakırçay Üniversitesien_US
dc.description.abstractIntroduction: During the current pandemic, a great effort is being made to understand COVID-19 and find an effective treatment. Still, there is no specific drug that has been approved by the FDA for the prevention or treatment of COVID-19. This studyaims to evaluate the effect of hydroxychloroquine (HCQ) treatment in COVID-19 patients. Methods: We retrospectively analyzed the clinical and radiological findings of COVID-19 patients that were treated between March 11-May 15 2020. Confirmation of a COVID-19 diagnosis was made according to a positive Real Time -Reverse Transcriptase Polimerase Chain Reaction (RT-PCR) result and/or with a consistent high-resolution computerized tomography (HRCT) findings. Following treatment, the clinical and radiological response, mortality and overall survival rates were evaluated. Results: 469 patients were included in the study. 58.8% of these patients were male and 41.2% of were female. 36 patients (7.7%) did not receive HCQ and 433 patients (92.3%) received HCQ. The groups who received and did not receive HCQ were at similar ages, had a similar gender distribution and smoking habits. There is no statistically significant difference for comorbidities between these two groups. No significant difference was found when the radiological regression times of the patients were compared. Mortality rates of the non-HCQ group and HCQ group were comparable (11% vs. 11% respectively). There is no statistical difference in overall survival (OS). Discussion and Conclusion: In this retrospective study, it was observed that the use of HCQ does not contribute to mortality and life expectancy in patients with Covid-19.en_US
dc.identifier.doi10.5505/ktd.2022.87259
dc.identifier.endpage106en_US
dc.identifier.issn2147-0758
dc.identifier.issue2en_US
dc.identifier.startpage97en_US
dc.identifier.trdizinid1130030en_US
dc.identifier.urihttps://doi.org/10.5505/ktd.2022.87259
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1130030
dc.identifier.urihttps://hdl.handle.net/20.500.14034/1742
dc.identifier.volume11en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofKocaeli Tıp Dergisien_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleEvaluation of Treatment Responses of COVID-19 Patients Receiving Hydroxychloroquine Treatment: a Retrospective Analysis in a Tertiary ReferenceHospital in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
1742.pdf
Boyut:
987.54 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu